US FDA grants Fast Track designation to empagliflozin for the treatment of chronic kidney disease in adults

The ongoing EMPA-KIDNEY study, initiated following promising exploratory results from the EMPA-REG OUTCOME trial, is evaluating the effect of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death in adults with and without diabetes.


Biospace Inc.